{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:48:10Z","timestamp":1773301690422,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Miguel Servet II fellowship (CPII18\/00018)"],"award-info":[{"award-number":["Miguel Servet II fellowship (CPII18\/00018)"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10096-019-03765-y","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T02:03:54Z","timestamp":1575338634000},"page":"647-656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Failure to complete treatment for latent tuberculosis infection in Portugal, 2013\u20132017: geographic-, sociodemographic-, and medical-associated factors"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8132-5645","authenticated-orcid":false,"given":"Alexis","family":"Sent\u00eds","sequence":"first","affiliation":[]},{"given":"Paula","family":"Vasconcelos","sequence":"additional","affiliation":[]},{"given":"Rita S\u00e1","family":"Machado","sequence":"additional","affiliation":[]},{"given":"Joan A.","family":"Cayl\u00e0","sequence":"additional","affiliation":[]},{"given":"M\u00f2nica","family":"Guxens","sequence":"additional","affiliation":[]},{"given":"Vasco","family":"Peixoto","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Carvalho","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"key":"3765_CR1","doi-asserted-by":"publisher","unstructured":"European Centre for Disease Prevention and Control. Review of reviews and guidelines on target groups, diagnosis, treatment and programmatic issues for implementation of latent tuberculosis management. Stockholm: ECDC; 2018. [cited 2019 10]. www.ecdc.europa.eu\nhttps:\/\/doi.org\/10.2900\/318458","DOI":"10.2900\/318458"},{"key":"3765_CR2","doi-asserted-by":"publisher","unstructured":"Comstock GW, Livesay VT WS. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974 [cited 2019 23];99:131\u20138. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/4810628: https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a121593","DOI":"10.1093\/oxfordjournals.aje.a121593"},{"key":"3765_CR3","doi-asserted-by":"publisher","unstructured":"L\u00f6nnroth K, Migliori GB, Abubakar I, D\u2019Ambrosio L, de Vries G, Diel R, et al Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015 [cited 2019 23];45:928\u201352. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25792630\nhttps:\/\/doi.org\/10.1183\/09031936.00214014","DOI":"10.1183\/09031936.00214014"},{"key":"3765_CR4","doi-asserted-by":"publisher","unstructured":"Rosales-Klintz S, Bruchfeld J, Haas W, Heldal E, Houben RMGJ, van Kessel F, et al Guidance for programmatic management of latent tuberculosis infection in the European Union\/European Economic Area. Eur Respir J 2019 17 [cited 2019 23];53:1802077. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30655449\nhttps:\/\/doi.org\/10.1183\/13993003.02077-2018","DOI":"10.1183\/13993003.02077-2018"},{"key":"3765_CR5","doi-asserted-by":"publisher","unstructured":"European Centre for Disease Prevention and Control\/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2018\u20132016 data. Stockholm: European Centre for Disease Prevention and Control, 2018. 2018 [cited 2019 7]. www.ecdc.europa.eu\/en\/\nhttps:\/\/doi.org\/10.2900\/1940","DOI":"10.2900\/1940"},{"key":"3765_CR6","unstructured":"Programa Nacional para a Infe\u00e7\u00e3o VIH\/SIDA. Dire\u00e7\u00e3o-Geral da Sa\u00fade. Infe\u00e7\u00e3o VIH, SIDA e Tuberculose em n\u00fameros \u2013 2014. [cited 2019 10]. https:\/\/www.dgs.pt\/estatisticas-de-saude\/estatisticas-de-saude\/publicacoes\/portugal-infecao-vih-sida-e-tuberculose-em-numeros-2014-pdf.aspx"},{"key":"3765_CR7","unstructured":"DGS. Tuberculose em Portugal Desafios e Estrat\u00e9gias. 2018 [cited 2019 7]. https:\/\/www.dgs.pt\/documentos-e-publicacoes\/tuberculose-em-portugal-desafiose-estrategias-2018-.aspx"},{"key":"3765_CR8","doi-asserted-by":"publisher","unstructured":"Fox GJ, Dobler CC, Marais BJ, Denholm JT. Preventive therapy for latent tuberculosis infection\u2014the promise and the challenges. Int J Infect Dis 2017 1 [cited 2019 23];56:68\u201376. https:\/\/www.ijidonline.com\/article\/S1201-9712(16)31223-1\/fulltext\nhttps:\/\/doi.org\/10.1016\/J.IJID.2016.11.006","DOI":"10.1016\/J.IJID.2016.11.006"},{"key":"3765_CR9","doi-asserted-by":"publisher","unstructured":"Sandgren A, Vonk Noordegraaf-Schouten M, van Kessel F, Stuurman A, Oordt-Speets A, van der Werf MJ. Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis 2016 17 [cited 2019 10];16:204. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27184748\nhttps:\/\/doi.org\/10.1186\/s12879-016-1550-y","DOI":"10.1186\/s12879-016-1550-y"},{"key":"3765_CR10","doi-asserted-by":"publisher","unstructured":"Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 2018 2 [cited 2019 10];379:440\u201353. http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1714283\nhttps:\/\/doi.org\/10.1056\/NEJMoa1714283","DOI":"10.1056\/NEJMoa1714283"},{"key":"3765_CR11","doi-asserted-by":"publisher","unstructured":"Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, et al Safety and side effects of rifampin versus isoniazid in children. N Engl J Med 2018 2 [cited 2019 10];379:454\u201363. http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1714284\nhttps:\/\/doi.org\/10.1056\/NEJMoa1714284","DOI":"10.1056\/NEJMoa1714284"},{"key":"3765_CR12","unstructured":"Ambrona de Marcos V, Bach Foradada P, Alsed\u00e0 Graells M, Duque Jim\u00e9nez T, Delgado Roche E, Aguilar Ariza R, et al [Compliance of latent tuberculosis infection treatment in a cohort of TB contacts]. Rev. Esp. Salud Publica 2018 [cited 2018 19];92. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30131485"},{"key":"3765_CR13","doi-asserted-by":"publisher","unstructured":"Fiske CT, Yan F-X, Hirsch-Moverman Y, Sterling TR, Reichler MR, Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk factors for treatment default in close contacts with latent tuberculous infection. Int J Tuberc Lung Dis 2014 1 [cited 2018 19];18:421\u20137. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24670696\nhttps:\/\/doi.org\/10.5588\/ijtld.13.0688","DOI":"10.5588\/ijtld.13.0688"},{"key":"3765_CR14","doi-asserted-by":"publisher","unstructured":"Moro RN, Borisov AS, Saukkonen J, Khan A, Sterling TR, Villarino ME, et al Factors associated with noncompletion of latent tuberculosis infection treatment: experience from the PREVENT TB Trial in the United States and Canada. Clin Infect Dis 2016 1;62:1390\u2013400. https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/ciw126\nhttps:\/\/doi.org\/10.1093\/cid\/ciw126","DOI":"10.1093\/cid\/ciw126"},{"key":"3765_CR15","doi-asserted-by":"publisher","unstructured":"Goswami ND, Hecker EJ, Vickery C, Ahearn MA, Cox GM, Holland DP, et al Geographic information system-based screening for TB, HIV, and Syphilis (GIS-THIS): a cross-sectional study. PLoS One 2012 2 [cited 2019 14];7:e46029. https:\/\/dx.plos.org\/10.1371\/journal.pone.0046029\nhttps:\/\/doi.org\/10.1371\/journal.pone.0046029","DOI":"10.1371\/journal.pone.0046029"},{"key":"3765_CR16","doi-asserted-by":"publisher","unstructured":"Sun W, Gong J, Zhou J, Zhao Y, Tan J, Ibrahim A, et al A spatial, social and environmental study of tuberculosis in China using statistical and GIS technology. Int. J. Environ. Res. Public Health 2015 27 [cited 2019 14];12:1425\u201348. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25633032\nhttps:\/\/doi.org\/10.3390\/ijerph120201425","DOI":"10.3390\/ijerph120201425"},{"key":"3765_CR17","doi-asserted-by":"publisher","unstructured":"Franco I, Sousa P, Gomes M, Oliveira A, Gaio AR, Duarte R Social profile of the highest tuberculosis incidence areas in Portugal. Rev Port Pneumol (English Ed) 2016 1 [cited 2019 28];22:50\u20132. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2173511515001621\nhttps:\/\/doi.org\/10.1016\/j.rppnen.2015.08.006","DOI":"10.1016\/j.rppnen.2015.08.006"},{"key":"3765_CR18","doi-asserted-by":"publisher","unstructured":"Felgueiras M, Cerqueira S, Gaio R, Felgueiras \u00d3, Duarte R Comparative study between tuberculosis incidence rates in the two largest metropolitan areas of Portugal. Arch Bronconeumol 2018 [cited 2019 8];54:595\u20136. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29884424\nhttps:\/\/doi.org\/10.1016\/j.arbres.2018.05.003","DOI":"10.1016\/j.arbres.2018.05.003"},{"key":"3765_CR19","unstructured":"WHO | Latent tuberculosis infection (LTBI) - FAQs. WHO 2017 [cited 2019 10]; https:\/\/www.who.int\/tb\/areas-of-work\/preventive-care\/ltbi\/faqs\/en\/"},{"key":"3765_CR20","unstructured":"World Health Organization. Latent tuberculosis infection Updated and consolidated guidelines for programmatic management. [cited 2019 10]. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/260233\/9789241550239-eng.pdf"},{"key":"3765_CR21","unstructured":"Hirsch-Moverman Y, Daftary A, Franks J, Colson PW Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008 [cited 2019 21];12:1235\u201354. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18926033"},{"key":"3765_CR22","doi-asserted-by":"publisher","unstructured":"Priest DH, Vossel LF, Sherfy EA, Hoy DP, Haley CA. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Clin Infect Dis 2004 15 [cited 2019 17];39:1764\u201371. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15578397\nhttps:\/\/doi.org\/10.1086\/425610","DOI":"10.1086\/425610"},{"key":"3765_CR23","doi-asserted-by":"publisher","unstructured":"LoBue PA, Moser KS Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003 15 [cited 2019 17];168:443\u20137. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12746255\nhttps:\/\/doi.org\/10.1164\/rccm.200303-390OC","DOI":"10.1164\/rccm.200303-390OC"},{"key":"3765_CR24","unstructured":"Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis 2010 [cited 2019 21];14:1104\u201311. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20819254"},{"key":"3765_CR25","doi-asserted-by":"publisher","unstructured":"Stuurman AL, Vonk Noordegraaf-Schouten M, van Kessel F, Oordt-Speets AM, Sandgren A, van der Werf MJ Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review. BMC Infect Dis 2016 8 [cited 2019 21];16:257. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27268103\nhttps:\/\/doi.org\/10.1186\/s12879-016-1549-4","DOI":"10.1186\/s12879-016-1549-4"},{"key":"3765_CR26","doi-asserted-by":"publisher","unstructured":"Belknap R, Holland D, Feng P-J, Millet J-P, Cayl\u00e0 JA, Martinson NA, et al Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection. Ann Intern Med 2017 21 [cited 2019 21];167:689. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29114781\nhttps:\/\/doi.org\/10.7326\/M17-1150","DOI":"10.7326\/M17-1150"},{"key":"3765_CR27","doi-asserted-by":"publisher","unstructured":"Shu C-C, Wu V-C, Yang F-J, Pan S-C, Lai T-S, Wang J-Y, et al Predictors and prevalence of latent tuberculosis infection in patients receiving long-term hemodialysis and peritoneal dialysis. PLoS One 2012 [cited 2019 23];7:e42592. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22916137\nhttps:\/\/doi.org\/10.1371\/journal.pone.0042592","DOI":"10.1371\/journal.pone.0042592"},{"key":"3765_CR28","doi-asserted-by":"publisher","unstructured":"Shu C-C, Hsu C-L, Lee C-Y, Wang J-Y, Wu V-C, Yang F-J, et al Comparison of the prevalence of latent tuberculosis infection among non-dialysis patients with severe chronic kidney disease, patients receiving dialysis, and the dialysis-unit staff: a cross-sectional study. PLoS One 2015 [cited 2019 23];10:e0124104. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25919813\nhttps:\/\/doi.org\/10.1371\/journal.pone.0124104","DOI":"10.1371\/journal.pone.0124104"},{"key":"3765_CR29","doi-asserted-by":"publisher","unstructured":"Lee M-R, Huang Y-P, Kuo Y-T, Luo C-H, Shih Y-J, Shu C-C, et al Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis. Clin Infect Dis 2016 16 [cited 2019 23];64:ciw836. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27986673\nhttps:\/\/doi.org\/10.1093\/cid\/ciw836","DOI":"10.1093\/cid\/ciw836"},{"key":"3765_CR30","doi-asserted-by":"publisher","unstructured":"Fan W-C, Ting W-Y, Lee M-C, Huang S-F, Chiu C-H, Lai S-L, et al Latent TB infection in newly diagnosed lung cancer patients-a multicenter prospective observational study. Lung Cancer 2014 1 [cited 2019 23];85:472\u20138. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25063540\nhttps:\/\/doi.org\/10.1016\/j.lungcan.2014.07.001","DOI":"10.1016\/j.lungcan.2014.07.001"},{"key":"3765_CR31","doi-asserted-by":"publisher","unstructured":"van Zyl Smit RN, Pai M, Yew WW, Leung CC, Zumla A, Bateman ED, et al Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J 2010 [cited 2019 23];35:27\u201333. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20044459\nhttps:\/\/doi.org\/10.1183\/09031936.00072909","DOI":"10.1183\/09031936.00072909"},{"key":"3765_CR32","unstructured":"ECDC. Programmatic management of latent tuberculosis infection in the European Union. 2018 [cited 2019 27]. https:\/\/ecdc.europa.eu\/en\/publications-data\/programmatic-management-latent-tuberculosis-infection-european-union"},{"key":"3765_CR33","doi-asserted-by":"publisher","unstructured":"Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, Blumberg HM, Venkatappa TK, Horsburgh CR, et al Latent tuberculous infection in the United States and Canada: who completes treatment and why? Int J Tuberc Lung Dis 2015 1 [cited 2019 21];19:31\u20138. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25519787\nhttps:\/\/doi.org\/10.5588\/ijtld.14.0373","DOI":"10.5588\/ijtld.14.0373"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03765-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-019-03765-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03765-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T19:35:38Z","timestamp":1606851338000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-019-03765-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["3765"],"URL":"https:\/\/doi.org\/10.1007\/s10096-019-03765-y","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,3]]},"assertion":[{"value":"11 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"In this study, patients were not directly involved; anonymized data were extracted from the national TB clinical notification and follow-up surveillance system (SVIG-TB) and analysed by authors at Directorate-General of Health, as part of their routine functions of surveillance and control of communicable diseases. The study was performed following the indications of the Helsinki Declaration (reviewed in Tokio, October 2004).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patient\u2019s data were anonymized prior to analysis and, for that reason, informed consent was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}